1, 25-dihydroxyvitamin D3 and its synthetic derivatives MC903 and EB1089 induce a partial tumoral phenotype reversal in a skin-equivalent system

Journal of Investigative Dermatology Symposium Proceedings

Volumn 1, Issue 1, 1996, Pages 87-93

  Mils, Valeric ^a   Basset Séguin, Nicole ^a   Moles, Jean Pierre ^a   Guilhou, Jean Jacques ^a  

^a Hopital Saint Charles   (France)

Author keywords

Vitamin D3lepithelial cancers

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIPOTRIOL; CALCITRIOL; DRUG DERIVATIVE; SEOCALCITOL;

ARTICLE; DRUG EFFECT; HUMAN; PHENOTYPE; SKIN; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; CALCITRIOL; HUMANS; PHENOTYPE; SKIN; SKIN NEOPLASMS;

EID: 0030112285     PISSN: 10870024     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Nornian AW, Scrgecv IN, Bishop JE, Okamura WH: Selective biological response by target organs (intestine, kidney, and bone) to 1, 25-dihydroxyvitamin D3 and two analogues. Camer Res 53:3935-3942, 1993
2. Kreutz M, Andrecsen R: Induction of human monocyte to macrophage maturation in vitro by 1, 25-dihydroxy vitamin D3. Blood 76:2457-2461, 1990
3. Suda T, Miyaura C, Abe E, Kuroki T: Modulation of cell differentiation, immune responses and tumor promotion by vitamin D compounds. J Ifane .A/nirr Res 4:1-48, 1986
4. Kato Y, Shimazu A, Iwamoto M, Nakashima K, Koike T, Suzuki F, Nislni Y, Sato K: Role of 1, 25-dihydrocholecalciferol in growth-plate cartilage: inhibition of terminal differentiation of chondrocytes in vitro and in vivo. Proc Natl Acad Sci USA 87:6522-6526, 1990
5. Wcrgcdal JE, Matsuyama T, Strong UD: Differentiation of normal human bone cells by transforming growth factor-beta and 1, 25(OH)2 vitamin D3. Metabolism 41:42-48, 1992
6. Bhalla AK, Williams MM, Lal S, Lydyard I'M: 1, 25-dihydrovitamin D3, but not retinoic acid, induces the differentiation of U937 cells. Clin Exp Immunol 76:274-277, 1989
7. Carlbcrg C, Bcndik I, Wyss A, Meier E, Sturzenbeckcr LJ, Grippo JF, Hunziker W: Two nuclear signalling pathways for vitamin D. Xature 361:657- 660, 1993
8. Morrison NA, Shine J, Fragonas JC, Vcrkcrst V, McMcnemy ML, Eisman JA: 1, 25-dihydroxyvitamin D-rcsponsive element and glucocorticoid repression in the ostcocalcin gene. Science 246:1158-1161, 1989
9. Yada Y, Ozeki T, Meguro S, Mori S, Nozawa Y: Signal transduction in the onset of terminal keratinocyte differentiation induced by 1 alpha, 25-dihydro.xyvitamin D3: role of protein kinasc C translocation. Biochctn Biophys Res Commun 163:1517-1522, 1989
10. Wali RK, Baum CL, Sitrin MD, Brasitus TA: 1, 25(OH)2 vitamin D3 stimulates membrane phosphoinositide turnover, activates protein kinasc C, and increases cytosolic calcium in rat colonie epithelium. J Clin Invest 85:1296-1303, 1990
11. Morelli S, De Doland AR, Boland RL: Generation of inositol phosphates, diacylglycerol and calcium fluxes in myoblasts treated with 1, 25-dihydrovitamin D3. Biochem J 289:675-679, 1993
12. Inohara S: Studies and perspectives of signal transduction in the skin. Exp Dcrmaiol 1:207-220, 1992
13. Farach-Carson MC, Scrgccv I, Norman AW: Nongenomic actions of 1, 25-dihydroxyvitamin D3 in rat osteosarcoma cells: structure-function studies using ligand analogs. Endocrinology 129:1876-1884, 1991
14. Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T: Regulation of terminal differentiation of cultured mouse epidermal cells by 1a, 25-dihydroxyvitamin D3. Endocrinology 3:1950-1957, 1983
15. Bikle DD, Gee E, Pillai S: Regulation of keratinocyte growth, differentiation, and vitamin D metabolism by analogs of l , 25-dihydroxyvitamin D. J Invest Dermatol 101:713-718, 1993
16. Lee SC, Ikai K, Ando Y, Imamura S: Effects of lalpha, 25-dihydroxyvitamin D3 on the transglutaminase activity of transformed mouse epidermal cells in culture. J Dermatol 16:7-11, 1989
17. Matsumoto K, Azuma Y, Kiyoki M, Okumura H, Hashimoto K, Yoshikawa K: Involvement of endogenously produced 1, 25-dihydroxy vitamin D3 in the growth and differentiation of human keratinocytes. Kiochim Biophys Acta 1092:311-318, 1991
18. Pillai S, Bibklc DD, Elias PM: Vitamin D and epidermal differentiation: evidence for a role of endogenously produced vitamin D metabolites in kcratinocytc differentiation. Skin Phanuacol 1:149-160, 1988
19. Saudners DE, Christensen C, Lawrence WD, Malviya VK, Malonc JM, Williams JR, Deepe G: Receptors for 1, 25-dihydroxyvitamin D3 in gynecologic neoplasm. Gynctol Ontol 44:131-136, 1992
20. Brehier A, Thomasset M: Human colon cell line HT-29: characterization of 1, 25-dihydroxyvitamin D3 receptor and induction of differentiation by the hormone. J Steroid Buxliem 29:265-270, 1988
21. Tsuclnya H, Morislnta H, Tomita K, Ueda Y, Tanaka M: Differenriaring and anritumor activities of 1 alpha, 25-dihydroxyvïtamin D3 ill vitro and 1 alphahydroxyvitamin D3 in vivo on human osteosarcoma. Orfhop Res 11:122-130, 1993
22. Colston KW, Berger U, Coombcs RC: Possible role for vitamin D in controlling breast cancer cell proliferation. Lautet 1:188-191, 1989
23. Albert DM, Marcus DM, Gallo JP, O'Brien JM: The antineoplastic effect of vitamin D in mice with rerinoblastoma. Inrest Ophthalmol l'is Sci 33:2354-2364, 1992
24. Matsunaga T, Yamamoto M, Mimura H, Ohta T, Kiyoki M, Ohba T, Naruchi T, Hosoi J, Kuroko T: l, 24(R)-dihydroxyvitamïn D3, a novel active form of vitamin D3 with high activity for inducing epidermal differentiation but decreased hypercalcémie activity. J Dermatol 17:135-142, 1990
25. Binderup L, Latini S, Binderup E, Bretting C, Calverley M, Hansen K: 20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses, Bioeltetn I'hartnafol 42:1569-1575, 1991
26. Colston KW, Mackay AG, James SY, Binderup L, Chander S, Coombes RC: EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Bioehcm 1'liannacol 44:2273-2280, 1992
27. Abe J, Nakano T, Nisbn Y, Matsumoto T, Ogata E, Ikeda K: A novel vitamin D3 analog, 22-oxa-l, 25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129:832-837, 1991
28. Zhou JY, Norman AW, Lubbert M, Collins ED, Uskokovic MR, Koeffler HP: Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone mobilization. Blood 74:82-93, 1989
29. Geusens I1, Vanderschueren D, Vcrstractcn A, Dcqueker J, Devos P, Bouillon R: Short-term course of 1, 25(OH)2D3 stimulates osteoblasts but not osteoclasts in osteoporosis and ostcoarthritis. Caldf Tissue Inl 49:168-173, 1991
30. Muramoto H, Haruki K, Yoshimura A, Mimo N, Oda K, Tofuku Y: Treatment of refractor)1 hypcrparathyroidism in patients on hemodialysis by intermittent oral administration of 1, 25(OH)2 vitamin D3. Nephron 58:288-294, 1991
31. Ritz E, Matthias S, Seidel H, Reichet H, Szabo A, Horl WH: Disturbed calcium metabolism in renal failure: pathogcncsts and therapeutic strategies. Kidney Int Suppl 38:537-42, 1992
32. De Rosa L, Montuoro A, De Laurenzi A: Therapy of "high risk" myelodysplastic syndromes with an association of low dose of Ara-C, retinoic acid and 1, 25-dihydroxyvitamin D3. Blamed Pliamamtner 46:211-217, 1992
33. El-Azhary RA, Peters MS, I'ittelkow MR, Kao PC, Muller SA: Efficacity of vitamin D3 derivatives in the treatment of psoriasis vulgaris: a preliminary report. Mayo Clin I'm 68:835-841, 1993
34. Murdoch D, Clissold SP: Calcipotriol: a review of its pharmacological properties and therapeutic use in psoriasis vulgaris. Drugs 43:415-429, 1992
35. Morimoto S, Yoshikawa K: Psoriasis and vitamin D3: a review of our experience. Arch Dermatol 125:231-234, 1989
36. Biklc DD, Pillai S, Gee E: Squamous carcinoma cell lines produce 1, 25 dihydroxyvitamin D, but fail to respond to its prodifferentialing effect. J Invest Dermatol 97:435-441, 1991
37. Sedman SA, Barbosa MS, Vass WC, Hubbert ML, Haas JA, Lowy DR, Schiller JT: The full length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize kcratinocytes in culture. J Virol 65:4860-4866, 1991
38. Moles JP, Schiller JT, Tesnière A, Leigh IM, Guilhou JJ, Basset-Séguin N: Analysis of HPV16 E6 and mutant p53-transfectcd keratinocytes in reconstituted epidermis suggests that wild-type p53 inhibits cytokeratin 19 expression. J Celt Sci 107:435-441, 1994
39. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Imtmtnol Methods 65:55-59, 1983
40. Prunicras M: Epidermal cell cultures as model for living skin epidermis. J Invest Diro;81:28S-33S, 1979
41. Leigh IM, Purkis PE, Whitehead P, Lane EB: Monospecific monoclonal antibodies to keratin 1 carboxy terminal (synthetic peptide) and to keratin 10 as markers of epidermal differentiation. Br J Dermatol 129:110-119, 1993
42. Purkis PE, Steel JB, Mackenzie 1C, Nathrath WBJ, Leigh IM, Lane EB: Antibody markers of basal cells in complex cpithelia.J Cell Sci 97:39-50, 1990
43. Stasiak PC, Purkis PE, Leigh IM, Lane EB: Keratin 19: predicted amino acid sequence and broad tissue distribution suggest it evolved from kcratinocytc keratins. J Invest Dermatol 92:707-716, 1989
44. Assclincau D, Dale BA, Bernard BA: Filaggrin production by cultured human epidermal keratinocytes and its regulation by retinoic acid. Differentiation 45:221-229, 1990
45. Simon M, Sebbag M, Haftek M, Vincent C, Girbal-Ncuhauscr E, Rakotoarivony J, Sommé G, Schmitt D, Serre G: Monoclonal antibodies to human epidermal filaggrin, some not recognizing profilaggrin. J Invest Dermatol 105:432-137, 1995
46. Eckert KL, Green H: Cloning of cDNAs specifying vitamin A-rcsponsive human keratins. Proc Xatl Acad Sci USA 81:4321-4325, 1984
47. Kopan R, Traska G, Fuchs E: Retinoid as important regulators of terminal differentiation: examining keratin expression in individual epidermal cells at various stages of keratinization. J Cell Biol 105:427-440, 1987
48. Régnier M, Darmon M: l , 25-dihydroxyvitamin D3 stimulates specifically the last steps of epidermal differentiation of cultured human keratinocytes. Differentiation 47:173-188, 1991
49. Watt FM, Kubler MD, Hotchin NA, Nicholson LJ, Adams JC: Regulation of kcratinocyte terminal differentiation by integrin-extracellular matrix interactions. J Cell Sci 106(Part 1):175-182, 1993
50. Hodivala KJ, Watt FM: Evidence that cadherins play a role in the downrcgulation of integrin expression that occurs during keratinocyte terminal differentiation. J Cell Biol 124:589-600, 1994
51. Ryynanen J, Jaakkola S, Engvall E, Peltonen J, Uitto J: Expression of beta 4 integrins in human skin: comparison of epidermal distribution with beta 1-integrin epitopes, and modulation by calcium and vitamin D3 in cultured keratinocytes. J Invest Dermatol 97:562-567, 1991
52. Sonnenberg A, Calafat J, Jansscn H, Daams H, Van Der Raaij-Helmer LM, Falcioni R, Kennel SJ, Aplin JD, Baker J, Loizidou M, Garrod D: Integrin a6//34 complex is located in bemidesmosomes, suggesting a major role in epidermal cell-basement membrane adhesion.J Cell Biol 113:907-917, 1991
53. Schule R, Umcsono K, Mangelsdorf DJ, Bolado J, Wesley Pike J, Evans RM: Jun-Fos and receptors for vitamins A and D recognize a common response clement in the human osteocalcin gene. Cell 61:497-504, 1990